4th Quarter - Report

TEVA PHARMACEUTICALS USA, INC. for TEVA PHARMACEUTICALS USA INC

Period 4th Quarter 2019 Filed Jan 21, 2020 Signed by Dolly Judge, Vice President, U.S. Government Affairs

Official filing
Firm
TEVA PHARMACEUTICALS USA, INC.
Client
TEVA PHARMACEUTICALS USA INC
Income
—
Expenses
$410,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

US-Mexico-Canada Agreement (issues relating to IP Chapter)

Foreign entity interest: Teva Pharmaceutical Industries, Ltd., as the indirect parent of Teva Pharmaceuticals USA Inc., has an interest in the issues listed.

LobbyistCovered position, as disclosed
DOLLY A JUDGE —
COLMAN BRENDAN RAGAN —

Contacted: SENATE; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR)

Health Issues HCR

HR 3199-Terminating the Extension of Rights Misappropriated Act of 2019; S.340/HR 965-Creating & Restoring Equal Access to Equivalent Samples Act ("Creates Act"); HR 985-Fast Generics Act; S.64-Preserve Access to Affordable Generic & Biosimilars Act; HR 1499-Protecting Consumer Access to Generic Drugs Act; HR 1344-Competitive Drugs Act of 2019; HR 938-Bringing Low Cost Options & Competition While Keeping Incentives for New Generics Act ("BLOCKING Act"); HR 1506-Fair & Immediate Release of Generic Drugs Act; HR 1520-Purple Book Continuity Act; HR 1503-Orange Book Transparency Act; S.344/HR 990-Hatch-Waxman Integrity Act; Stronger Patents Act; S.1895-Lower Health Care Costs Act; S. 2543-Prescription Drug Pricing Reduction Act; and Administration review of drug pricing policies.

Foreign entity interest: Teva Pharmaceutical Industries, Ltd., as the indirect parent of Teva Pharmaceuticals USA Inc., has an interest in the issues listed.

LobbyistCovered position, as disclosed
MICHAEL BRZICA New Legislative Counsel, Rep. Lee Terry (2007-2009)
DOLLY A JUDGE —
COLMAN BRENDAN RAGAN —

Contacted: SENATE; Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: H.R. 3199 (116th), H.R. 938 (116th), S. 340 (116th), S. 344 (116th), S. 1895 (116th), H.R. 1506 (116th), S. 2543 (116th), H.R. 965 (116th), S. 64 (116th), H.R. 1499 (116th), H.R. 1520 (116th), H.R. 985 (116th), H.R. 1344 (116th), H.R. 990 (116th), H.R. 1503 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.